PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Positive growth while TRAW shows revenue decline. John Neff would investigate competitive advantages.
-27.15%
Cost reduction while TRAW shows 33.33% growth. Joel Greenblatt would examine competitive advantage.
73.30%
Positive growth while TRAW shows decline. John Neff would investigate competitive advantages.
89.46%
Margin expansion while TRAW shows decline. John Neff would investigate competitive advantages.
8.30%
R&D growth above 1.5x TRAW's 4.99%. Michael Burry would check for spending discipline.
28.80%
G&A change of 28.80% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth above 1.5x TRAW's 1.60%. Michael Burry would check for inefficiency.
14.70%
Total costs growth above 1.5x TRAW's 1.61%. Michael Burry would check for inefficiency.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-27.15%
D&A reduction while TRAW shows 33.33% growth. Joel Greenblatt would examine efficiency.
-16.20%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
54.13%
EBITDA margin growth while TRAW declines. John Neff would investigate advantages.
-15.23%
Both companies show declining income. Martin Whitman would check industry conditions.
54.52%
Operating margin growth while TRAW declines. John Neff would investigate advantages.
98.15%
Other expenses growth above 1.5x TRAW's 29.22%. Michael Burry would check for concerning trends.
-12.38%
Both companies show declining income. Martin Whitman would check industry conditions.
55.64%
Pre-tax margin growth while TRAW declines. John Neff would investigate advantages.
-98.15%
Tax expense reduction while TRAW shows 100.00% growth. Joel Greenblatt would examine advantage.
-9.33%
Both companies show declining income. Martin Whitman would check industry conditions.
56.84%
Net margin growth while TRAW declines. John Neff would investigate advantages.
-5.41%
EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
-8.33%
Diluted EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
2.98%
Share count reduction below 50% of TRAW's 0.05%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of TRAW's 0.05%. Michael Burry would check for concerns.